Head to head
Semaglutide against Danuglipron
People looking for a GLP-1 they can swallow land on both. One of them has an approved oral form and a trial record measured in tens of thousands of people; the other has a discontinued development programme and no product. The pages exist so the second fact is as easy to find as the first.
Column A
SemaglutideSemaglutide (GLP-1 receptor agonist)
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Column B
DanuglipronDanuglipron (oral small-molecule GLP-1 agonist)
Pfizer's oral small-molecule GLP-1 agonist whose development was discontinued after tolerability and safety signals.
Side by side, on the facts we can check
| Attribute | Semaglutide | Danuglipron |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) | Development discontinued; not approved |
| Half-life | ~7 days | Short (was studied as daily dosing) |
| Molecular weight | 4,113.6 Da | ~556 Da |
| Mechanism | Activates the GLP-1 receptor, increasing insulin secretion when glucose is elevated, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake. | Activates the GLP-1 receptor as an orally available small molecule rather than an injected peptide. |
| Human studies cited | 5 | 4 |
| Legal status, US | FDA-approved, prescription only | Investigational, not approved |
Frequently asked questions
What is the difference between Semaglutide and Danuglipron?
Semaglutide: A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction. Danuglipron: Pfizer's oral small-molecule GLP-1 agonist whose development was discontinued after tolerability and safety signals.
Which has stronger research evidence, Semaglutide or Danuglipron?
This database does not grade compounds. It counts what was run in people: 5 of the 5 studies cited on the Semaglutide profile were human work, against 4 of 4 for Danuglipron. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Semaglutide and Danuglipron FDA-approved?
Semaglutide: FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management). Danuglipron: Development discontinued; not approved.
Related posts
Blog articles that cover Semaglutide or Danuglipron, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Longevity / Sep 8, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.